EVOK Valuation

Evoke Pharma Inc

Add to Watchlist

Advanced Chart

5.300

+0.1(1.923%)1D

Overview
Forecast
Valuation
Earnings

EVOK Relative Valuation

EVOK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EVOK is overvalued; if below, it's undervalued.

Historical Valuation

Evoke Pharma Inc (EVOK) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.55 is considered Undervalued compared with the five-year average of -4.99. The fair price of Evoke Pharma Inc (EVOK) is between 10.99 to 12.85 according to relative valuation methord. Compared to the current price of 5.16 USD , Evoke Pharma Inc is Undervalued By 53.1%.

Relative Value

Fair Zone

10.99-12.85

Current Price：5.16

53.1%

Undervalued

-7.88

Trailing

Forward

0.00

EV/EBITDA

Evoke Pharma Inc. (EVOK) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.08. The thresholds are as follows: Strongly Undervalued below -0.53, Undervalued between -0.53 and -0.22, Fairly Valued between 0.38 and -0.22, Overvalued between 0.38 and 0.69, and Strongly Overvalued above 0.69. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-3.18

EV/EBIT

Evoke Pharma Inc. (EVOK) has a current EV/EBIT of -3.18. The 5-year average EV/EBIT is -1.69. The thresholds are as follows: Strongly Undervalued below -13.73, Undervalued between -13.73 and -7.71, Fairly Valued between 4.33 and -7.71, Overvalued between 4.33 and 10.35, and Strongly Overvalued above 10.35. The current Forward EV/EBIT of -3.18 falls within the Historic Trend Line -Fairly Valued range.

0.55

Evoke Pharma Inc. (EVOK) has a current PS of 0.55. The 5-year average PS is 5.99. The thresholds are as follows: Strongly Undervalued below -16.93, Undervalued between -16.93 and -5.47, Fairly Valued between 17.45 and -5.47, Overvalued between 17.45 and 28.91, and Strongly Overvalued above 28.91. The current Forward PS of 0.55 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Evoke Pharma Inc. (EVOK) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.13. The thresholds are as follows: Strongly Undervalued below -0.75, Undervalued between -0.75 and -0.31, Fairly Valued between 0.57 and -0.31, Overvalued between 0.57 and 1.00, and Strongly Overvalued above 1.00. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Evoke Pharma Inc. (EVOK) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.13. The thresholds are as follows: Strongly Undervalued below -0.75, Undervalued between -0.75 and -0.31, Fairly Valued between 0.57 and -0.31, Overvalued between 0.57 and 1.00, and Strongly Overvalued above 1.00. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Evoke Pharma Inc (EVOK) has a current Price-to-Book (P/B) ratio of 2.40. Compared to its 3-year average P/B ratio of 1.49 , the current P/B ratio is approximately 61.47% higher. Relative to its 5-year average P/B ratio of -6.16, the current P/B ratio is about -139.03% higher. Evoke Pharma Inc (EVOK) has a Forward Free Cash Flow (FCF) yield of approximately -31.84%. Compared to its 3-year average FCF yield of -109.50%, the current FCF yield is approximately -70.93% lower. Relative to its 5-year average FCF yield of -82.44% , the current FCF yield is about -61.38% lower.

2.40

P/B

Median3y

1.49

Median5y

-6.16

-31.84

FCF Yield

Median3y

-109.50

Median5y

-82.44

Competitors Valuation Multiple

The average P/S ratio for EVOK's competitors is 4.14, providing a benchmark for relative valuation. Evoke Pharma Inc Corp (EVOK) exhibits a P/S ratio of 0.55, which is -86.62% above the industry average. Given its robust revenue growth of 47.06%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

TNF Pharmaceuticals Inc

Loss

6.71M

ADIL.O

Adial Pharmaceuticals Inc

Loss

8.22M

CYCN.O

Cyclerion Therapeutics Inc

3.88

8.38M

VYNE.O

Vyne Therapeutics Inc

20.41

-65.15%

8.21M

Performance Decomposition

Market capitalization of EVOK decreased by 0.95% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 2.55M to 3.75M.

The secondary factor is the Margin Expansion, contributed -15.70%to the performance.

Overall, the performance of EVOK in the past 1 year is driven by Revenue Growth. Which is more sustainable.

47.06%

2.55M → 3.75M

Revenue Growth

-15.70%

-49.67 → -41.87

Margin Expansion

-32.31%

-3.78 → -2.56

P/E Change

-0.95%